CD22 and acute lymphoblastic leukemia: For example, we found our predicted markers EBF1, VPREB3, and CCN2 to be positively correlated with the known B‐cell surface markers CD22, CD79a, CD19, and CD24 in both datasets, aligning with our predicted upregulation of EBF1, VPREB3, and CCN2 in B‐ALL compared to T‐ALL (Table 3).